Dana–Farber Cancer Institute

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, November 2, 2023

ET

Key Points: 
  • ET
    WATERTOWN, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today reported financial results for the third quarter ended September 30, 2023, and provided business updates on its pipeline of protein degraders.
  • Collaboration Revenues: Collaboration revenues were $4.7 million for the third quarter of 2023 compared to $9.6 million for the third quarter of 2022.
  • Net Loss: Net loss was $52.9 million for the third quarter of 2023 compared to a net loss of $43.0 million for the third quarter of 2022.
  • Cash and Cash Equivalents: As of September 30, 2023, Kymera had $435 million in cash, cash equivalents, and investments.

Mass General Brigham Nurses Vote to Strike at South Shore Endoscopy Center in Braintree as Highly Profitable MGB Rejects Nurses' Efforts to Secure a Fair Contract to Help Them Provide High-Quality Gastrointestinal Care

Retrieved on: 
Friday, November 3, 2023

BRAINTREE, Mass., Nov. 3, 2023 /PRNewswire/ -- Registered nurses at Brigham and Women's Harbor Medical Associates South Shore Endoscopy (SSEC), represented by the Massachusetts Nurses Association, voted on Wednesday, November 1 to authorize a one-day strike because Mass General Brigham executives have refused to agree to a fair contract that would provide competitive pay, reasonable time off, and daily overtime, enabling nurses to continue providing the high-quality gastrointestinal care patients deserve.

Key Points: 
  • "Mass General Brigham has repeatedly rejected our efforts and has forced us into a position to take a strike vote.
  • "MGB makes enormous profits and pays its executives millions of dollars but refuses to compromise with nurses who provide exceptional care day in and day out."
  • The strike vote gives the nurses on the SSEC Bargaining Committee authorization to hold a one-day strike if necessary.
  • SSEC nurses would then plan to hold a 24-hour strike unless MGB agreed to a fair contract by that date.

Oncoclínicas opens first Cancer Center in Brazil as an International Collaborative Member of Dana-Farber Cancer Institute

Retrieved on: 
Wednesday, November 1, 2023

The estimated investment by Oncoclinicas in the new Cancer Center is BRL 93 million, including infrastructure, technology, and operations.

Key Points: 
  • The estimated investment by Oncoclinicas in the new Cancer Center is BRL 93 million, including infrastructure, technology, and operations.
  • These facilities will be expanded to accommodate the new Oncoclínicas Cancer Center in Belo Horizonte e Nova Lima, an International Collaborative Member of Dana-Farber Cancer Institute.
  • "The Oncoclínicas cancer center in Belo Horizonte is the first outside the United States to receive the designation of international collaborating member of the Dana Farber Cancer Institute.
  • "Among other collaborative efforts, our multidisciplinary discussions contribute to democratizing cancer care for every patient across our operations in Brazil.

Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

Retrieved on: 
Wednesday, October 25, 2023

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB).

Key Points: 
  • SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB).
  • “We wholeheartedly welcome Dr. Smith to Oncternal’s Prostate Cancer Scientific Advisory Board,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.
  • He has published extensively on the treatment and prevention of bone metastases, prostate cancer survivorship, and novel androgen receptor pathway inhibitors.
  • He completed a fellowship in Medical Oncology at Dana Farber Cancer Institute and a postdoctoral fellowship at Massachusetts Institute of Technology.

Aspira Women’s Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research

Retrieved on: 
Wednesday, October 25, 2023

AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases today announced that a poster on an in-development miRNA-based ovarian cancer test was presented at the AACR Special Conference in Cancer Research: Ovarian Cancer, held on October 5, 2023 in Boston, MA.

Key Points: 
  • AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases today announced that a poster on an in-development miRNA-based ovarian cancer test was presented at the AACR Special Conference in Cancer Research: Ovarian Cancer, held on October 5, 2023 in Boston, MA.
  • The poster, entitled: “Improving the diagnostic accuracy of an ovarian cancer triage test using a joint miRNA-protein model,” highlighted data showing miRNA’s potential to improve the diagnostic accuracy of non-invasive diagnostic tests.
  • The study combined serum protein and patient clinical information (metadata) from Aspria’s ovarian cancer registry studies with miRNA determined by the Elias laboratory.
  • The analysis shows the potential for improving ovarian cancer diagnostics by combining our trusted technology with miRNA.

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

Retrieved on: 
Sunday, October 22, 2023

These results were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.

Key Points: 
  • These results were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.
  • “These Phase 2 monotherapy study results demonstrate that palazestrant (OP-1250) has the potential to become a best-in-class endocrine therapy and improve upon current standard of care treatments for women living with metastatic breast cancer.
  • In addition to being well-tolerated, palazestrant has demonstrated compelling progression-free survival as monotherapy in a heavily pretreated patient population,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology.
  • A copy of the oral presentation is available on Olema’s website under the Science section of the Olema website.

Precede Biosciences Unveils Groundbreaking Clinical Data for its Pioneering Liquid Biopsy Platform at ESMO 2023 and Simultaneously Publishes in Nature Medicine

Retrieved on: 
Saturday, October 21, 2023

BOSTON, Oct. 21, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, today announced the first clinical data from its proprietary liquid biopsy platform were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, and simultaneously published in Nature Medicine. The data demonstrate the platform's unique capability to inform and impact clinical decisions by providing resolution into the activation status of individual disease-defining genes and pathways genome-wide, from a simple blood draw.

Key Points: 
  • In this patient’s case, the signal identified by the Precede blood-based test was confirmed subsequently by tissue biopsy and immunohistochemistry (IHC), enabling this information to be used for clinical care.
  • In the future, a simple blood draw and testing with the Precede platform may be sufficient for clinical decision-making alone.
  • This very real case demonstrates the power of the Precede platform and its potential to impact precision medicine.
  • A copy of the presentation and a link to the manuscript can be found in the News section of the website.

THE PROSTATE CANCER FOUNDATION AND BAYER ANNOUNCE FIRST EVER BAYER-PCF DAROLUTAMIDE CHALLENGE AWARDS

Retrieved on: 
Wednesday, October 25, 2023

LOS ANGELES, Oct. 25, 2023 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and Bayer today announced two 2023 Bayer-PCF Darolutamide Challenge Awards totaling $2 million to support clinical investigations on darolutamide in prostate cancer.

Key Points: 
  • LOS ANGELES, Oct. 25, 2023 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and Bayer today announced two 2023 Bayer-PCF Darolutamide Challenge Awards totaling $2 million to support clinical investigations on darolutamide in prostate cancer.
  • In 2019, the U.S. Food and Drug Administration approved Bayer's Nubeqa® (darolutamide), an androgen receptor inhibitor (ARI), for the treatment of adults with non-metastatic, castration-resistant prostate cancer (nmCRPC).
  • In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer (mHSPC), or metastatic prostate cancer patients receiving their first line of hormonal treatment.
  • The teams awarded 2023 Bayer-PCF Darolutamide Challenge Awards are:
    Co-Investigators: Heather Jacene, MD, Mary-Ellen Taplin, MD, Jacob Berchuck, MD, all of Dana-Farber Cancer Institute; Steve Balk, MD, Beth Israel Deaconess Medical Center

The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at 38th Annual Meeting

Retrieved on: 
Wednesday, October 25, 2023

MILWAUKEE, Oct. 25, 2023 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) received a record-breaking number of abstract submissions in 2023, more than 1,600, and has announced titles and authors for 30 accepted Late-breaking Abstracts (LBA). The abstracts will be presented at SITC's upcoming 38th Annual Meeting & Pre-Conference Programs taking place November 1–5, 2023, in San Diego, CA and virtually.

Key Points: 
  • The abstracts will be presented at SITC's upcoming 38th Annual Meeting & Pre-Conference Programs taking place November 1–5, 2023, in San Diego, CA and virtually.
  • SITC also invites you to attend the virtual press briefing of the society's 38th Annual Meeting (SITC 2023) beginning at 12:00 p.m. PDT on Wednesday, Nov. 1, 2023.
  • The abstracts will be presented at SITC's upcoming 38th Annual Meeting & Pre-Conference Programs taking place November 1–5, 2023, in San Diego, CA and virtually.
  • The abstracts selected for the press briefing represent an array of the top advances in cancer immunotherapy research.

GC Cell Joins U.S Cancer Moonshot Project

Retrieved on: 
Wednesday, October 25, 2023

YONGIN, South Korea, Oct. 24, 2023 /PRNewswire/ -- GC Cell, led by CEO James Park, has announced its participation in CancerX, part of the U.S. Cancer Moonshot project. The Cancer Moonshot, an initiative by the Biden administration, aims to reduce cancer patient mortality rates by over 50% over the next 25 years. In February of this year, CancerX, a public-private collaboration led by the Moffitt Cancer Center and the Digital Medicine Society, was established to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot.

Key Points: 
  • YONGIN, South Korea, Oct. 24, 2023 /PRNewswire/ -- GC Cell, led by CEO James Park, has announced its participation in CancerX, part of the U.S. Cancer Moonshot project.
  • The Cancer Moonshot, an initiative by the Biden administration, aims to reduce cancer patient mortality rates by over 50% over the next 25 years.
  • In February of this year, CancerX, a public-private collaboration led by the Moffitt Cancer Center and the Digital Medicine Society, was established to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot.
  • Through Cancer Moonshot participation, GC Cell aims to highlight the importance and potential of cell therapy in cancer treatment.